Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

BACKGROUND: Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to anticancer drug resistance, but such correlation is unclear in sorafenib resistance of HCC. METHODS: Six sorafenib-naive HCC cell li...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shen, Y-C, Ou, D-L, Hsu, C, Lin, K-L, Chang, C-Y, Lin, C-Y, Liu, S-H, Cheng, A-L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553537/
https://ncbi.nlm.nih.gov/pubmed/23257894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados